Use PEVs as a biocompatible delivery platform to transport trophic factors to ocular tissues, enhancing retention, barrier penetration, and localized effects for tissue repair and anti-inflammation.

Develop controlled loading of PEVs with complementary biologics (e.g., peptides, antibodies, nucleic acids), enabling targeted delivery and tunable release for multi-mechanistic therapy (anti-angiogenic, anti-inflammatory, regenerative).

https://doi.org/10.1016/j.biomaterials.2025.123205

Design and optimize nanoparticles based on highly biocompatible organic polymers to enhance ocular surface retention, corneal penetration, and controlled release—enabling effective delivery of therapeutics for corneal disorders (e.g., wound repair, inflammation control, anti-angiogenesis, dry-eye management).

Engineer the nanoparticles to co-deliver complementary biologics/small molecules (e.g., trophic factors, anti-inflammatory and anti-angiogenic agents) with tunable dosing and release profiles, aiming to accelerate epithelial healing, suppress pathological neovascularization, reduce inflammation, and improve tear-film homeostasis.

https://doi.org/10.7150/thno.65098

Engineer hydrogel networks that more closely match native vitreous optics, viscoelasticity, and shear-thinning behavior across temperature and shear rates relevant to saccades and surgery.

Incorporate broad-spectrum anti-inflammatory and antioxidant modules and explore synergistic combinations (small molecules, peptides, biologics) to modulate post-operative pathways without elevating IOP.

https://doi.org/10.1016/j.ijbiomac.2024.133467

Develop biocompatible, minimally invasive conductive cryogels with tunable porosity, mechanics, and electrical impedance to interface with soft tissues and support regeneration.

Engineer on-demand, electrically triggered release of therapeutics from the cryogel while ensuring cytocompatibility and functional efficacy in models of tissue repair (e.g., neural/muscle, ocular surface).

https://doi.org/10.1021/acsomega.5c02628

Formulate platelet-derived extracellular vesicles (PEVs) as stable aerosols for tracheal instillation/nebulization, optimizing aerodynamic diameter, mucus penetration, and alveolar deposition while preserving EV integrity and bioactivity; establish lung biodistribution, retention, and safety in fibrosis and tumor-bearing models.

Engineer PEVs to carry antifibrotic and anticancer payloads (e.g., pathway modulators, nucleic acids, immuno-adjuvants) with tunable release and cell-type targeting (epithelium, fibroblasts, macrophages, tumor cells), aiming to attenuate fibrotic remodeling and suppress tumor growth within the pulmonary microenvironment.

https://doi.org/10.1016/j.biomaterials.2007.05.006

https://doi.org/10.1016/j.biomaterials.2009.03.010

Design biocompatible nanoparticles that persist in the joint, penetrate cartilage/synovium, and provide controlled release to reduce inflammation and catabolism while protecting chondrocytes.

Enable co-delivery (or sequential release) of complementary agents—anti-inflammatory, anti-catabolic, and pro-regenerative—to slow structural degeneration, support matrix repair, and improve joint function.

https://doi.org/10.1016/j.biopha.2024.116717